Combination of calretinin, MALAT1, and GAS5 as a potential prognostic biomarker to predict disease progression in surgically treated mesothelioma patients
Pleural mesothelioma is a fatal cancer of the pleural cavity, primarily caused by asbestos. Overall survival (OS) after diagnosis is poor and the long latency period of the disease after asbestos exposure is responsible for the still increasing incidence of mesothelioma worldwide [1,2]. Several options are available for the treatment of pleural mesothelioma to improve OS, ranging from multimodal therapy including surgery and chemotherapy to, chemotherapy or immunotherapy [3,4]. Monitoring the disease progression after treatment is essential, but imaging techniques are of limited value in mesothelioma, in contrast to severa...
Source: Lung Cancer - April 24, 2024 Category: Cancer & Oncology Authors: Laura V. Klotz, Swaantje Casjens, Georg Johnen, Dirk Taeger, Alexander Brik, Florian Eichhorn, Laura F örster, Nina Kaiser, Thomas Muley, Christa Stolp, Marc Schneider, Jan Gleichenhagen, Thomas Brüning, Hauke Winter, Martin Eichhorn, Daniel G. Weber Tags: Research Paper Source Type: research
Integrated bioinformatics and machine learning analysis identify ACADL as a potent biomarker of reactive mesothelial cells
This study aimed to identify and validate potential biomarkers that distinguish mesothelial cells from mesothelioma cells through machine learning combined with immunohistochemistry (IHC) experiments. We integrated the gene expression matrix from three GEO datasets (GSE2549, GSE12345, GSE51024) to analyze the differently expressed gene (DEGs) between normal and mesothelioma tissues. (Source: American Journal of Pathology)
Source: American Journal of Pathology - April 21, 2024 Category: Pathology Authors: Yige Yin, Qianwen Cui, Jiarong Zhao, Qiang Wu, Qiuyan Sun, Hong-qiang Wang, Wulin Yang Tags: Regular Article Source Type: research
Genomic characterization and detection of potential therapeutic targets for peritoneal mesothelioma in current practice
Clin Exp Med. 2024 Apr 20;24(1):80. doi: 10.1007/s10238-024-01342-y.ABSTRACTPeritoneal mesothelioma (PeM) is an aggressive tumor with limited treatment options. The current study aimed to evaluate the value of next generation sequencing (NGS) of PeM samples in current practice. Foundation Medicine F1CDx NGS was performed on 20 tumor samples. This platform assesses 360 commonly somatically mutated genes in solid tumors and provides a genomic signature. Based on the detected mutations, potentially effective targeted therapies were identified. NGS was successful in 19 cases. Tumor mutational burden (TMB) was low in 10 cases, ...
Source: Clinical Lung Cancer - April 20, 2024 Category: Cancer & Oncology Authors: Job P van Kooten Michelle V Dietz Hendrikus Jan Dubbink Cornelis Verhoef Joachim G J V Aerts Eva V E Madsen Jan H von der Th üsen Source Type: research
Analysis of invasive diagnostic techniques for pathological confirmation of pleural mesothelioma
CONCLUSIONS: In our review, pleural biopsy performed with image guidance was the test that had the highest diagnostic yield, so it should be considered as the initial invasive test for the study of mesothelioma.PMID:38642958 | DOI:10.1016/j.rxeng.2023.03.005 (Source: Radiologia)
Source: Radiologia - April 20, 2024 Category: Radiology Authors: H G ómez Herrero B Álvarez Galván Source Type: research
Cancers, Vol. 16, Pages 1587: Multimodal Treatment of Pleural Mesothelioma with Cytoreductive Surgery and Hyperthermic Intrathoracic Chemotherapy: Impact of Additive Chemotherapy
E. Eichhorn
Michael Ried
Cytoreductive surgery (CRS) combined with hyperthermic intrathoracic chemoperfusion (HITOC) is a promising treatment strategy for pleural mesothelioma (PM). The aim of this study was to evaluate the impacts of this multimodal approach in combination with systemic treatment on disease-free survival (DFS) and overall survival (OS). In this retrospective multicenter study, clinical data from patients after CRS and HITOC for PM at four high-volume thoracic surgery departments in Germany were analyzed. A total of 260 patients with MPM (220 epithelioid, 40 non-epithelioid) underwent CRS and HITOC ...
Source: Cancers - April 20, 2024 Category: Cancer & Oncology Authors: Laura V. Klotz Julia Zimmermann Karolina M üller Julia Kov ács Mohamed Hassan Michael Koller Severin Schmid Gunnar Huppertz Till Markowiak Bernward Passlick Hans-Stefan Hofmann Hauke Winter Rudolf A. Hatz Martin E. Eichhorn Michael Ried Tags: Article Source Type: research
Genomic characterization and detection of potential therapeutic targets for peritoneal mesothelioma in current practice
AbstractPeritoneal mesothelioma (PeM) is an aggressive tumor with limited treatment options. The current study aimed to evaluate the value of next generation sequencing (NGS) of PeM samples in current practice. Foundation Medicine F1CDx NGS was performed on 20 tumor samples. This platform assesses 360 commonly somatically mutated genes in solid tumors and provides a genomic signature. Based on the detected mutations, potentially effective targeted therapies were identified. NGS was successful in 19 cases. Tumor mutational burden (TMB) was low in 10 cases, and 11 cases were microsatellite stable. In the other cases, TMB and...
Source: Clinical and Experimental Medicine - April 20, 2024 Category: Research Source Type: research
Mental health and wellbeing in mesothelioma: A qualitative study exploring what helps the wellbeing of those living with this illness and their informal carers
CONCLUSIONS: Findings have implications for nurses and other key professionals working in healthcare, community and legal settings supporting this client group, and for those living with mesothelioma who want to understand ways to enhance their own wellbeing.PMID:38640636 | DOI:10.1016/j.ejon.2024.102572 (Source: European Journal of Oncology Nursing)
Source: European Journal of Oncology Nursing - April 19, 2024 Category: Nursing Authors: Stephanie Ejegi-Memeh Virginia Sherborne Catriona Mayland Angela Tod Bethany H Taylor Source Type: research
Therapeutic Strategies to Improve the Treatment of Pleural Mesothelioma
Curr Med Chem. 2024 Apr 16. doi: 10.2174/0109298673268206240405084558. Online ahead of print.ABSTRACTPleural mesothelioma is a rare neoplastic disease with aggressive features. Patient survival is poor due to the lack of early symptoms and the absence of effective therapeutic strategies. The development of pleural mesothelioma is mainly associated with asbestos exposure and related chronic inflammation. From a molecular-based perspective, this disease is a heterogeneous tumor lacking actionable alterations. The median overall survival of patients affected by this tumor does not exceed 16 months from diagnosis. Molecular an...
Source: Current Medicinal Chemistry - April 17, 2024 Category: Chemistry Authors: Luca Mirra Giovanni L Beretta Daniela Lisini Angela Marcianti Eleonora Spampinato Cristina Corno Matteo Costantino Angelo Corsico Giulia Maria Stella Paola Perego Source Type: research
Diffuse pleural mesotheliomas with genomic near-haploidization: a newly recognized subset with distinct clinical, histologic, and molecular features
CONCLUSIONS: GNH defines an aggressive subtype of mainly biphasic DPMs in younger patients with recurrent alterations in SETDB1 and TP53. The enrichment in biphasic histology and TILs, together with our preliminary ICB response data and anecdotal clinical trial data, suggests that further evaluation of immunotherapy may be warranted in this subset.PMID:38630790 | DOI:10.1158/1078-0432.CCR-24-0085 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 17, 2024 Category: Cancer & Oncology Authors: Soo-Ryum Yang Gowtham Jayakumaran Jamal Benhamida Christopher A Febres Aldana Rachel Fanaroff Jason Chang Erika Gedvilaite Liliana B Villafania Jennifer L Sauter Michael Offin Marjorie G Zauderer Marc Ladanyi Source Type: research
Therapeutic Strategies to Improve the Treatment of Pleural Mesothelioma
Curr Med Chem. 2024 Apr 16. doi: 10.2174/0109298673268206240405084558. Online ahead of print.ABSTRACTPleural mesothelioma is a rare neoplastic disease with aggressive features. Patient survival is poor due to the lack of early symptoms and the absence of effective therapeutic strategies. The development of pleural mesothelioma is mainly associated with asbestos exposure and related chronic inflammation. From a molecular-based perspective, this disease is a heterogeneous tumor lacking actionable alterations. The median overall survival of patients affected by this tumor does not exceed 16 months from diagnosis. Molecular an...
Source: Current Medicinal Chemistry - April 17, 2024 Category: Chemistry Authors: Luca Mirra Giovanni L Beretta Daniela Lisini Angela Marcianti Eleonora Spampinato Cristina Corno Matteo Costantino Angelo Corsico Giulia Maria Stella Paola Perego Source Type: research
Diffuse pleural mesotheliomas with genomic near-haploidization: a newly recognized subset with distinct clinical, histologic, and molecular features
CONCLUSIONS: GNH defines an aggressive subtype of mainly biphasic DPMs in younger patients with recurrent alterations in SETDB1 and TP53. The enrichment in biphasic histology and TILs, together with our preliminary ICB response data and anecdotal clinical trial data, suggests that further evaluation of immunotherapy may be warranted in this subset.PMID:38630790 | DOI:10.1158/1078-0432.CCR-24-0085 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 17, 2024 Category: Cancer & Oncology Authors: Soo-Ryum Yang Gowtham Jayakumaran Jamal Benhamida Christopher A Febres Aldana Rachel Fanaroff Jason Chang Erika Gedvilaite Liliana B Villafania Jennifer L Sauter Michael Offin Marjorie G Zauderer Marc Ladanyi Source Type: research
Therapeutic Strategies to Improve the Treatment of Pleural Mesothelioma
Curr Med Chem. 2024 Apr 16. doi: 10.2174/0109298673268206240405084558. Online ahead of print.ABSTRACTPleural mesothelioma is a rare neoplastic disease with aggressive features. Patient survival is poor due to the lack of early symptoms and the absence of effective therapeutic strategies. The development of pleural mesothelioma is mainly associated with asbestos exposure and related chronic inflammation. From a molecular-based perspective, this disease is a heterogeneous tumor lacking actionable alterations. The median overall survival of patients affected by this tumor does not exceed 16 months from diagnosis. Molecular an...
Source: Current Medicinal Chemistry - April 17, 2024 Category: Chemistry Authors: Luca Mirra Giovanni L Beretta Daniela Lisini Angela Marcianti Eleonora Spampinato Cristina Corno Matteo Costantino Angelo Corsico Giulia Maria Stella Paola Perego Source Type: research
Circulating SMRP and CA ‐125 before and after pleurectomy decortication for pleural mesothelioma
ConclusionsLongitudinal changes in SMRP levels corresponded with a radiographic presence of disease in a subset of patients. SMRP surveillance could aid in detection of local recurrences, whereas CA-125 could be helpful in recognizing abdominal recurrences. (Source: Thoracic Cancer)
Source: Thoracic Cancer - April 17, 2024 Category: Cancer & Oncology Authors: Juuso Paajanen,
Ahmed Sadek,
William G. Richards,
Yue Xie,
Emanuele Mazzola,
Kristina Sidopoulos,
John Kuckelman,
Ritu R. Gill,
Raphael Bueno Tags: ORIGINAL ARTICLE Source Type: research
Extensive surgical resections for rare pleural neoplasms: a single-center experience with a yolk sac tumor and synovial sarcoma
Pleural neoplasms are rare and can be subdivided into pleural metastasis and primary pleural neoplasms. Non-mesothelioma primary pleural neoplasms are a diverse group of extremely rare pathologies. (Source: World Journal of Surgical Oncology)
Source: World Journal of Surgical Oncology - April 16, 2024 Category: Cancer & Oncology Authors: Tom Vandaele, Jan Van Slambrouck, Patrick Sch öffski, Herlinde Dumez, Birgit Weynand, Raf Sciot, Annalisa Barbarossa, An-Lies Provoost, Kristof Van de Voorde, Yves Debaveye, Sofian Bouneb, Philippe Nafteux and Laurens J. Ceulemans Tags: Case Report Source Type: research
Myocardial metastasis from ZEB1- and TWIST-positive spindle cell carcinoma of the esophagus: A case report
CONCLUSION: To the best of our knowledge, there have been no prior reports of cardiac metastasis of esophageal SCC. This case highlights our experience with a patient with esophageal SCC who progressed rapidly and died from the disease, with the autopsy examination showing cardiac metastasis.PMID:38617457 | PMC:PMC11008411 | DOI:10.3748/wjg.v30.i11.1636 (Source: World Journal of Gastroenterology : WJG)
Source: World Journal of Gastroenterology : WJG - April 15, 2024 Category: Gastroenterology Authors: Yoshihiro Shibata Hirofumi Ohmura Kazuki Komatsu Kosuke Sagara Atsuji Matsuyama Ryuji Nakano Eishi Baba Source Type: research
